Management consensus of inflammatory bowel disease for the Asia-Pacific region

Journal of Gastroenterology and Hepatology (Australia)

Volumn 21, Issue 12, 2006, Pages 1772-1782

  Ouyang, Qin ^a   Tandon, Rakesh ^d   Goh, K L ^e   Pan, Guo Zong ^b   Fock, K M ^f   Fiocchi, Claudio ^g   Lam, S K ^h   Xiao, Shu Dong ^c  

^a SICHUAN UNIVERSITY   (China)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d Pushpawati Singhania Research Institute   (India)

^e UNIVERSITY OF MALAYA   (Malaysia)

^f CHANGI GENERAL HOSPITAL   (Singapore)

^g LERNER RESEARCH INSTITUTE   (United States)

^h UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Asia Pacific; Consensus; Inflamatory bowel disease; Management

Indexed keywords

ALICAFORSEN; ANTIBIOTIC AGENT; AZATHIOPRINE; BALSALAZIDE; BUDESONIDE; CERTOLIZUMAB PEGOL; CIPROFLOXACIN; CYCLOSPORIN; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METRONIDAZOLE; NATALIZUMAB; OLSALAZINE; PREDNISONE; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; RECOMBINANT INTERLEUKIN 10; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ASIA; CLINICAL FEATURE; COLON RESECTION; CONSENSUS; CROHN DISEASE; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG DOSE REGIMEN; ENTERITIS; ENTEROCOLITIS; ETHNIC DIFFERENCE; GENETIC SUSCEPTIBILITY; GEOGRAPHIC DISTRIBUTION; HUMAN; INFECTIOUS COMPLICATION; LEUKAPHERESIS; NUTRITIONAL SUPPORT; PATHOGENESIS; PERIANAL ABSCESS; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

EID: 33750432201     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2006.04674.x     Document Type: Review

References (65)

1. Morita N, Toki S, Hirohashi T et al. Incidence and prevalence of inflammatory bowel disease in Japan: nationwide epidemiological survey during the year 1991. J. Gastroenterol. 1995; 30 (Suppl. 8): 1-4.
2. Radhakrishnan S, Zubaidi G, Daniel M, Sachdev GK, Mohan AN. Ulcerative colitis in Oman. A prospective study of the incidence and disease pattern from 1987 to 1994. Digestion 1997; 58: 266-70.
3. Yang SK, Hong WS, Min YI et al. Incidence and prevalence of ulcerative colitis in the Songpa-Kangdong District, Seoul, Korea, 1986-1997. J. Gastroenterol. Hepatol. 2000; 15: 1037-42.
4. Leong RW, Lau JY, Sung JJ. The epidemiology and phenotype of Crohn's disease in the Chinese population. Inflamm. Bowel Dis. 2004; 10: 646-51.
5. Al-Ghamdi AS, Al-Mofleh IA, Al-Rashed RS et al. Epidemiology and outcome of Crohn's disease in a teaching hospital in Riyadh. World J. Gastroenterol. 2004; 10: 1341-4.
6. Sood A, Midha V, Sood N, Bhatia AS, Avasthi G. Incidence and prevalence of ulcerative colitis in Punjab, North India. Gut 2003; 52: 1587-90.
7. Lee YM, Fock K, See SJ, Ng TM, Khor C, Teo EK. Racial differences in the prevalence of ulcerative colitis and Crohn's disease in Singapore. J. Gastroenterol. Hepatol. 2000; 15: 622-5.
8. Ouyang Q, Tandon R, Gol KL et al. The emergence of inflammatory bowel disease in the Asian Pacific region. Curr. Opin. Gastroenterol. 2005; 21: 408-13.
9. Tan YM, Goh KL. Ulcerative colitis in a multiracial Asian country: racial differences and clinical presentation in Malaysian patients. World J. Gastroenterol. 2005; 11: 5859-62.
10. Jiang XL, Cui HF. An analysis of 10218 ulcerative colitis cases in China. World J. Gastroenterol. 2002; 8: 158-61.
11. Ling KL, Ooi CJ, Luman W, Cheong WK, Choen FS, Ng HS. Clinical characteristics of ulcerative colitis in Singapore, a multiracial city-state. J. Clin. Gastroenterol. 2002; 35: 144-8.
12. Kitahora T, Utsunomiya T, Yokota A. Epidemiological study of ulcerative colitis in Japan: incidence and familial occurrence. The Epidemiology Group of the Research Committee of Inflammatory Bowel Disease in Japan. J. Gastroenterol. 1995; 30 (Suppl. 8): 5-8.
13. Park ER, Yang SK, Myung SJ et al. Familial occurrence of ulcerative colitis in Korea. Korean J. Gastroenterol. 2000; 36: 770-4.
14. A case-control study of ulcerative colitis in relation to dietary and other factors in Japan. The Epidemiology Group of the Research Committee of Inflammatory Bowel Disease in Japan. J. Gastroenterol. 1995; 30 (Suppl. 8): 9-12.
15. Nam SW, Yang SK, Jung HY et al. Appendectomy and the risk of developing ulcerative colitis: results after control of smoking factor. Korean J. Gastroenterol. 1998; 32: 55-60.
16. Law NM, Lim CC, Chong R, Ng HS. Crohn's disease in the Singapore Chinese population. J. Clin. Gastroenterol. 1998; 26: 27-9.
17. Okada M, Sakurai T, Yao T et al. Clinical course and long-term prognosis of Crohn's disease in Japan. J. Gastroenterol. 1994; 29: 406-14.
18. Hiwatashi N, Yao T, Watanabe H et al. Long-term follow-up study of ulcerative colitis in Japan. J. Gastroenterol. 1995; 30 (Suppl. 8): 13-16.
19. Iida M, Yao T, Okada M. Long-term follow-up study of Crohn's disease in Japan. The Research Committee of Inflammatory Bowel Disease in Japan. J. Gastroenterol. 1995; 30 (Suppl. 8): 17-19.
20. Inoue N, Tamura K, Kinouchi Y et al. Lack of common NOD2 variants in Japanese patients with Crohn's disease. Gastroenterology 2002; 123: 86-91.
21. Croucher PJ, Mascheretti S, Hampe J et al. Haplotype structure and association to Crohn's disease of CARD15 mutations in two ethnically divergent populations. Eur. J. Hum. Genet. 2003; 11: 6-16.
22. Leong RW, Armuzzi A, Ahmad T et al. NOD2/CARD15 gene polymorphisms and Crohn's disease in the Chinese population. Aliment. Pharmacol. Ther. 2003; 17: 1465-70.
23. Sands BE. From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. Gastroenterology 2004; 126: 1518-32.
24. Calkins BM, Lilienfeld AM, Garland CF, Mendeloff AI. Trends in incidence rates of ulcerative colitis and Crohn's disease. Dig. Dis. Sci. 1984; 29: 913-20.
25. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand. J. Gastroenterol. Suppl. 1989; 170: 2-6;discussion 16-19.
26. Myren J, Bouchier IA, Watkinson G, Softley A, Clamp SE, de Dombal FT. The OMGE multinational inflammatory bowel disease survey 1976-1986. A further report on 3175 cases. Scand. J. Gastroenterol. Suppl. 1988; 144: 11-19.
27. Shivananda S, Hordijk ML, Ten Kate FJ, Probert CS, Mayberry JF. Differential diagnosis of inflammatory bowel disease. A comparison of various diagnostic classifications. Scand. J. Gastroenterol. 1991; 26: 167-73.
28. Chinese Society of Gastroenterology. Suggested guideline for the diagnosis and treatment of inflammatory bowel disease. Chin. J. Dig. Dis. 2001; 2: 202-8.
29. Anand BS, Malhotra V, Bhattacharya SK et al. Rectal histology in acute bacillary dysentery. Gastroenterology 1986; 90: 654-60.
30. Liu TH, Pan GZ, Chen MZ. Crohn's disease. Clinicopathologic manifestations and differential diagnosis from enterocolonic tuberculosis. Chin. Med. J. (Engl.) 1981; 94: 431-40.
31. Bhargava DK, Tandon HD, Chawla TC, Shriniwa S, Tandon BN, Kapur BML. Diagnosis of ileocecal and colonic tuberculosis by colonoscopy. Gastrointest. Endosc. 1985; 31: 68-70.
32. Tandon HD, Prakash A. Pathology of intestinal tuberculosis and its distinction from Crohn's disease. Gut 1972; 13: 260-9.
33. Anand BS, Schneider FE, El-Zaatari FA, Shawar RM, Clarridge JE, Graham DY. Diagnosis of intestinal tuberculosis by polymerase chain reaction on endoscopic biopsy specimens. Am. J. Gastroenterol. 1994; 89: 2248-9.
34. Gan HT, Ouyang Q, Bu H. Polymerase chain reaction assay in differentiating intestinal tuberculosis from Crohn's disease. Chin. J. Dig. 2001; 21: 215-18.
35. Lee RG. The colitis of Behcet's syndrome. Am. J. Surg. Pathol. 1986; 10: 888-93.
36. Ogata H, Hibi T. Cytokine and anti-cytokine therapies for inflammatory bowel disease. Curr. Pharm. Des. 2003; 9: 1107-13.
37. Chourasia MK, Jain SK. Pharmaceutical approaches to colon targeted drug delivery systems. J. Pharm. Pharm. Sci. 2003; 6: 33-66.
38. Kohgo Y, Ashida T, Maemoto A, Ayabe T. Leukocytapheresis for treatment of IBD. J. Gastroenterol. 2003; 38 (Suppl. 15): 51-4.
39. Isbister WH, Hubler M. Inflammatory bowel disease in Saudi Arabia: presentation and initial management. J. Gastroenterol. Hepatol. 1998; 13: 1119-24.
40. Hanauer SB, Sandborn W, Practice Parameters Committee of the American College of Gastroenterology. Management of Crohn's disease in adults. Am. J. Gastroenterol. 2001; 96: 635-43.
41. Kornbluth A, Sachar DB, Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults (update). American College of Gastroenterology, Practice Parameters Committee. Am. J. Gastroenterol. 2004; 99: 1371-85.
42. Egan LJ, Sandborn WJ. Advances in the treatment of Crohn's disease. Gastroenterology 2004; 126: 1574-81.
43. Carter MJ, Lobo AJ, Travis SP, IBD Section, British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004; 53 (Suppl. 5): V1-16.
44. Hanauer SB. Medical therapy for ulcerative colitis 2004. Gastroenterology 2004; 126: 1582-92.
45. Fiocchi C. Inflammatory bowel disease pathogenesis: therapeutic implications. Chin. J. Dig. Dis. 2005; 6: 6-9.
46. Andoh A, Ogawa A, Kitamura K et al. Suppression of interleukin-1beta- and tumor necrosis factor-α-induced inflammatory responses by leukocytapheresis therapy in patients with ulcerative colitis. J. Gastroenterol. 2004; 39: 1150-7.
47. Sawada K, Kusugami K, Suzuki Y et al. Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment. Am. J. Gastroenterol. 2005; 100: 1362-9.
48. Targan SR, Hanauer SB, van Deventer SJH et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N. Engl. J. Med. 1997; 337: 1029-35.
49. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9.
50. Present DH, Rutgeerts P, Targan S et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N. Engl. J. Med. 1999; 340: 1398-405.
51. Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 2005; 353: 2462-76.
52. Baert FJ, Noman M, Vermeire S et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's ileocolitis. N. Engl. J. Med. 2003; 348: 601-8.
53. Sandborn WJ, Hanauer SB, Katz S et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001; 121: 1088-94.
54. Schreiber S, Rutgeerts P, Fedorak RN et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005; 129: 807-18.
55. Schreiber S, Nicolaus S, Malchow H et al. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease. Gastroenterology 2001; 120: 1339-46.
56. Ghosh S, Goldin E, Gordon FH et al. Natalizumab for active Crohn's disease. N. Engl. J. Med. 2003; 348: 24-32.
57. Berger JR, Koralnik IJ. Progressive multifocal leukoencephalopathy and natalizumab: unforseen consequences. N. Engl. J. Med. 2005; 353: 414-16.
58. Schreiber S, Fedorak RN, Nielsen OH et al. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Gastroenterology 2000; 119: 1461-72.
59. Mannon PJ, Fuss IJ, Mayer L et al. Anti-interleukin-12 antibody for active Crohn's disease. N. Engl. J. Med. 2004; 351: 2069-79.
60. Ito H, Takazoe M, Fukuda Y et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 2004; 126: 989-96.
61. Korzenik JR, Dieckegraefe BK, Valentine JF, Hausman DF, Gilbert MJ. Sargramostin for active Crohn's disease. N. Engl. J. Med. 2005; 352: 2193-201.
62. Sinha A, Nightingale JMD, West KP, Berlanga-Acosta J, Playford RJ. Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colis or proctitis. N. Engl. J. Med. 2003; 349: 350-7.
63. Musch E, Andus T, Kruis W et al. Interferon-β-1a for the treatment of steroid-refractory ulcerative colitis: a randomized, double-blind, placebo-controlled trial. Clin. Gastroenterol. Hepatol. 2005; 3: 581-6.
64. Kanauchi O, Mitsuyama K, Araki Y, Andoh A. Modification of intestinal flora in the treatment of inflammatory bowel disease. Curr. Pharm. Des. 2003; 9: 333-46.
65. Sandborn WJ, Targan SR. Biologic therapy of inflammatory bowel disease. Gastroenterology 2002; 122: 1592-608.